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When energy supply is low, organisms respond by slowing aging and increasing resistance to diverse age-
related pathologies. Targeting the mechanisms underpinning this response may therefore treat multiple dis-
orders through a single intervention. Here, we discuss AMP-activated protein kinase (AMPK) as an integrator
and mediator of several pathways and processes linking energetics to longevity. Activated by low energy,
AMPK is both prolongevity and druggable, but its role in some pathologies may not be beneficial. As such,
activating AMPK may modulate multiple longevity pathways to promote healthy aging, but unlocking its
full potential may require selective targeting toward substrates involved in longevity assurance.Introduction
Advances in public health have dramatically increased the num-
ber of people surviving into old age (Christensen et al., 2009).
Although human populations worldwide are living longer, we
are not necessarily aging gracefully. Patient age is the single
biggest risk factor for themajority of complex diseases, including
cancer, metabolic disease, and neurodegenerative disorders.
Current biomedical strategy is to treat each of these pathologies
in separation, targeting their unique proximal causes to alleviate
them. Unfortunately, the prevalence of comorbidity in the elderly
limits the impact of such a strategy; two-thirds of the elderly in
the United States have multiple chronic diseases (CDC, 2013).
Therefore, even substantial progress on a single disease may
have only marginal effects on overall disease-free healthspan
(Goldman et al., 2013).
An alternative approach to tackle age-onset pathologies is to
target their commonality: the aging process itself. Although ag-
ing has long been appreciated as a risk factor, modern medicine
has largely ignored it as a therapeutic target. Aging seemed sim-
ply too complex a phenotype to study, being the result of multi-
ple genetic and environmental factors too intricate to untangle.
This paradigm was irreversibly shifted in the late 20th century
by elegant experiments in the nematode C. elegans, which
demonstrated that single gene mutations could dramatically
prolong lifespan andmaintain animals in a youthful state (Kenyon
et al., 1993). Conservation of these genetic effects in fruit flies,
mouse, and long-lived human populations gave birth to a new
field: the genetics of aging (Fontana et al., 2010). The overriding
premise is that unlike chronological age, physiological age is
malleable, and mechanisms that modulate it can be exploited
to reduce overall disease risk (Figure 1).
Dietary restriction (DR), the reduction of food intake without
malnutrition, serves as a physiologically relevant proof of princi-
ple that a single intervention can provide broad-spectrum dis-
ease benefits. DR elicits a physiological low-energy state, and
this switch, mediated by conserved nutrient-sensing pathways,
delays aging in species ranging from yeast to primates (Mair
and Dillin, 2008). DR confers protection to multiple age-related
diseases, including neurodegenerative disease, kidney disease,
autoimmune disease, stroke, osteoporosis, glaucoma, cardio-
vascular disease, metabolic disease, and many forms of cancer
(Masoro, 2002). Understanding and targeting molecular media-10 Cell Metabolism 20, July 1, 2014 ª2014 Elsevier Inc.tors of DR might allow us to harness its therapeutic potential
while bypassing dietary interventions and the negative physio-
logical consequences of low energy. In this review, we discuss
evidence for and against AMP-activated protein kinase (AMPK)
as a conserved link between energetics and longevity, including
the tripartite effects of AMPK on aging-related pathways, pro-
cesses, and pathologies.
AMPK
AMPK is highly conserved across eukaryotes and serves as an
ancestral energy sensor (Hardie et al., 2012). When cellular en-
ergy is low, AMPK is activated and targets a range of physiolog-
ical processes, the net response of which is an increase in
energy production and a coordinated decrease in ATP usage.
AMPK exists as a heterotrimer comprised of a catalytic a subunit
with regulatory b and g subunits (Xiao et al., 2011). Phosphoryla-
tion of the a subunit at Thr172 is required for the kinase activity of
AMPK (Hawley et al., 1996) and activates its kinase activity
greater than 100-fold. The major upstream kinase targeting this
site is liver kinase B1 (LKB1) (Hawley et al., 2003; Shaw et al.,
2004; Woods et al., 2003), though two other AMPK kinases
have also been identified: calcium/calmodulin-dependent kinase
kinase b (CaMKKb) (Hawley et al., 2005; Woods et al., 2005) and
transforming growth factor-b-activated kinase 1 (Tak1) (Momci-
lovic et al., 2006). In the context of energy stress, LKB1 is the pre-
dominant AMPK-kinase (Tsou et al., 2011).
Nucleotide binding also acutely tunes AMPK to cellular energy
status. The g subunit contains four potential nucleotide-binding
sites, two of which can bind AMP, ADP, or ATP in a competitive
manner. Under low-energy conditions, the AMP/ADP:ATP ratio
increases, and AMP/ADP binds to AMPK in place of ATP (Xiao
et al., 2011). This nucleotide binding exchange has a three-
pronged effect on AMPK activity. Binding of AMP allosterically
activates AMPK 2- to 10-fold and promotes a Thr172 phosphor-
ylation by LKB1 (Gowans et al., 2013), while both AMP and ADP
protect AMPK against dephosphorylation at a Thr172 (Oakhill
et al., 2011; Xiao et al., 2011), most likely by inducing conforma-
tional changes that inhibit phosphatase access.
Given the conservation of both AMPK and the DR response,
AMPKmakes an appealingmechanistic link between energy sta-
tus, DR, and lifespan. Supporting this idea, lifespan extension in
the nematodeC. elegans via dilution of the E. coli food source on
Figure 1. Comorbidities and Age-Related Pathologies
Each bar represents pathological state of an individual patient from birth to
death. Green equals no pathology. As each chronic disease (CD) presents, a
decrease in health is portrayed by increased heat of color.
(A) Patients over 65 rarely have one age-related pathology in isolation, but
instead have multiple comorbidities that develop concurrently.
(B) Therefore, eradicating one disease (CD1) in its entirety will not dramatically
increase disease-free life.
(C) Targeting age-related frailty and systemic disease risk might alternatively
delay the onset of multiple pathologies and greatly improve healthy aging.
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subunits of AMPK, AAK-2 (Greer et al., 2007a). Reducing glycol-
ysis and glucose metabolism by feeding C. elegans 2-deoxy-D-
glucose also increases lifespan in an aak-2-dependent manner
(Schulz et al., 2007). Furthermore, aak-2 is required for the
extended lifespan seen when C. elegans deprived of food enters
a diapause-like arrest in either an early larval stage (Fukuyama
et al., 2012) or an alternate dauer development stage (Narbonne
and Roy, 2009). In a Drosophila study employing a DR protocol
where only the yeast component of the fly diet is reduced,
restoring AMP:ATP ratio by supplementing the animals with
adenine completely blocks lifespan extension, while the delayed
aging seen in AMP biosynthesis mutants is suppressed by domi-
nant-negative AMPK (Stenesen et al., 2013). Importantly, the
term DR is used to describe a variety of regimens, including
changes in caloric intake, nutritional composition, or food avail-
ability. Though multiple DR paradigms activate AMPK in worms
(A. Brunet, personal communication), AMPK is not required
for lifespan extension by all of them. For example, aak-2 is not
required for lifespan extension in worms fed diluted bacteria in
liquid culture, despite robust lifespan extension (Greer and
Brunet, 2009; Mair et al., 2009). Why AMPK is not univer-
sally required deserves further exploration. Explanations could
involve employment of different AMPK isoforms or secondary
signaling events elicited under the alternative metabolic or envi-
ronmental conditions.
The majority of mammalian data describing effects of food
intake on AMPK activity comes from work on acute starvation,
and whether chronic DR activates AMPK is dependent upon
the DR protocol used and the tissue examined (Canto´ and
Auwerx, 2011). Increases in DR severity from 5% to 40% induce
progressive activation of AMPK in rat liver and mammary carci-
nomas (Jiang et al., 2008). Long-term DR also increases AMPKa
Thr172 phosphorylation in mouse heart (Edwards et al., 2010)
and skeletal muscle (Palacios et al., 2009). However, examples
exist where chronic DR fails to activate AMPK (Gonzalez et al.,
2004) in mouse and even suppresses it in rat liver (To et al.,2007). As in worms, basic husbandry regimes and DR protocols
vary between groups studying DR in flies, mice, and monkeys
alike (Mair and Dillin, 2008), and more work is needed to deter-
mine the reliance of these differing regimes on AMPK.
AMPK Is a Prolongevity Kinase
Activating AMPK is sufficient to extend lifespan in model organ-
isms. Increasing expression of aak-2 inC. elegans increases life-
span by 13% and mimics DR in well-fed animals (Apfeld et al.,
2004). Similar increases in lifespan are also seen in transgenic
worms expressing a modified AMPK-g subunit (Greer et al.,
2007a), in which the AMP binding pocket is mutated at
conserved residues analogous to mutations that induce consti-
tutively active AMPK in mammals (Arad et al., 2002). More
recently, a 38% median increase in lifespan was shown in
C. elegans expressing a truncated form of aak-2 containing
only the catalytic domain, which uncouples its activation from
nucleotide binding (Mair et al., 2011). AMPK is highly conserved
across eukaryotes (Hardie, 2007), and this conservation applies
to its ability to modulate lifespan. Overexpression of the single
Drosophila AMPK-a subunit in either muscle or the fat body
extends lifespan in the fruit fly (Stenesen et al., 2013), as does
overexpression of LKB1 (Funakoshi et al., 2011).
Anti-Aging Small Molecules and AMPK
AMPK is activated by a surprisingly wide array of small mole-
cules, increasing its appeal as a longevity target. However, as
we outline here, many of these effects are indirect, and work in
model organisms has yet to fully elucidate the tissue and cell
types AMPK acts in to promote lifespan. Indeed, activation of
AMPK in certain tissues or conditions might in fact be damaging
to health (see AMPK and Aging Pathologies), highlighting a need
to selectively activate AMPK or target specific substrates if
we are to translate work in model systems to promote healthy
human aging.
Metformin
Many classical agonists activate AMPK indirectly by altering
the AMP/ADP:ATP balance in the cell. Such drugs include the
biguanides metformin and phenformin, which disrupt mito-
chondrial function by inhibiting electron transport chain complex
I, and 5-aminoimidazole-4-carboxamide-1-D-ribo-furanoside
(AICAR), which cells convert to an AMP analog, ZMP. Although
these compounds promote longevity in some settings, the direct
role of AMPK remains unclear. The beneficial effect of metformin
on health is more robust than its effects on aging per se. Metfor-
min is one of the most widely prescribed treatments for type II
diabetes, and patients takingmetformin show protection against
cancer independently of its effects on diabetes (Gallagher and
LeRoith, 2011). However, despite frequent use of metformin as
an AMPK agonist in biochemical studies, whether AMPK is actu-
ally the key mediator of the effects of metformin on health is un-
certain. Metformin can potentially bind directly to AMPK (Zhang
et al., 2012), but a more accepted paradigm is that AMPK is acti-
vated as a secondary effect of metformin perturbing mitochon-
drial electron transport chain function (Hardie, 2006). Metformin
can also exert physiological effects independent of AMPK. Met-
formin can inhibit target of rapamycin complex I (TORC1) in the
absence of AMPK (Kalender et al., 2010), and block glucose
production in mouse primary hepatocytes lacking both AMPKCell Metabolism 20, July 1, 2014 ª2014 Elsevier Inc. 11
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and glucagon (Miller et al., 2013).
C. elegans fed 50 mMmetformin maintain a youthful state and
display a 50% increase in median lifespan that is dependent on
aak-2 (Onken and Driscoll, 2010). Interestingly, unlike genetic
activation of AMPK (Greer et al., 2007a), the effects of metformin
on longevity do not require FOXO/DAF-16, a prolongevity tran-
scription factor activated by reduced insulin/IGF-1 signaling
(rIIS) (Kenyon, 2010). Instead, metformin-induced longevity in
the worm depends upon the ortholog of mammalian Nrf2,
SKN-1, which also plays a role in lifespan extension by DR
(Bishop and Guarente, 2007). Common husbandry procedure
for C. elegans is to coculture them with live E. coli that act as a
food source for the worm, and this two-organism situation can
present problems in small-molecule studies. Elegant data from
Cabreiro et al. (2013) show that metformin indeed extends
C. elegans lifespan via AMPK, but does so indirectly by altering
folate metabolism in the live E. coli. Metformin fails to increase
lifespan of worms cultured on dead bacteria.
Whether the effect of metformin on aging in other species also
functions via the microbiome is an area worthy of exploration
(Heintz and Mair, 2014). Indeed, the effect of metformin on
longevity in organisms other than C. elegans is less than clear.
Despite robustly activating AMPK and reducing stored triacylgly-
cerides (TAGs), metformin does not increase Drosophila lifespan
(Slack et al., 2012). Failure to promote longevity may occur
because ubiquitous activation of AMPK in the fly is detrimental
or because metformin fails to induce AMPK in the relevant tis-
sues for longevity. Much of the work examining the effects of
AMPK agonists on rodent lifespan has been performed on
short-lived strains predisposed to cancer, and in this context
both phenformin and metformin increase lifespan (Anisimov
et al., 2005; Dilman and Anisimov, 1980). Effects in wild-type
rodent strains are mixed. Metformin does not increase lifespan
of Fischer 344 rats (Smith et al., 2010), but a recent report shows
beneficial effects of chronic metformin feeding starting in mid-
dle-aged C57BL/6 mice (Martin-Montalvo et al., 2013). The ef-
fects on longevity in this case are dose dependent and small:
1% dietary metformin shortens lifespan, while 0.1% increases
median lifespan of male mice by 5%. The body of metformin
data thus holds promise—especially regarding healthspan as
opposed to lifespan—but reveals an abundance of off-target ef-
fects, providing a clear example of the need for target and tissue
specificity in the search for small-molecule DR mimetics.
Resveratrol
Resveratrol is a polyphenol that improves metabolic fitness of
mice and monkeys fed a high-fat diet (HFD) (Baur et al., 2006;
Jimenez-Gomez et al., 2013). Resveratrol was first shown to in-
crease replicative lifespan of budding yeast (Howitz et al., 2003),
and its effect on aging is conserved. Resveratrol increases life-
span in C. elegans, Drosophila (Wood et al., 2004), and mice
on a HFD (Baur et al., 2006) in a manner suggested to function
via the NAD-dependent deacetylase Sir2p and its orthologs.
Following initial discoveries, however, both the ability of resver-
atrol to directly agonize Sir2p (Kaeberlein et al., 2005) and the
robustness of its effects on lifespan in lower organisms were
challenged (Bass et al., 2007), leading to speculation on whether
the physiological effects of resveratrol might be mediated by
alternative targets. An additional consequence of resveratrol12 Cell Metabolism 20, July 1, 2014 ª2014 Elsevier Inc.administration is activation of AMPK (Baur et al., 2006), and
this mechanism may mediate some of its beneficial effects on
health. Mice lacking either AMPKa1 or AMPKa2 have severely
blunted responses to resveratrol, and resveratrol activates
AMPK in mouse embryonic fibroblasts lacking SirT1 function
(Um et al., 2010). Furthermore, AMPK can indirectly activate
the mammalian Sir2p ortholog, SirT1, by altering the NAD/
NADH ratio (Canto´ et al., 2009), suggesting an alternative indirect
route for sirtuin activation by resveratrol.
Recent data attempting to reconcile the requirement of SirT1
or AMPK activation for the effects of resveratrol report critical
effects of dose. Though resveratrol activates AMPK at all con-
centrations, this effect is SirT1 dependent at low doses, but inde-
pendent at higher doses (Price et al., 2012). As such, the relevant
contributions of these two fuel sensors to any effects of resver-
atrol on longevity may be context specific. Recent work by Hub-
bard et al. (2013) demonstrates that resveratrol can allosterically
activate SirT1 in a mechanism that requires a single amino acid,
Glu230. Whether this allosteric interaction is required for the
effects of resveratrol and other sirtuin-activating compounds
on longevity requires evaluation. Irrespective of whether the
beneficial effects of resveratrol require AMPK and SirT1 to func-
tion epistatically or in concert, it is becoming increasingly clear
that AMPK plays a key role. Indeed, comparison of whole-
genome transcriptional changes induced by resveratrol (Viswa-
nathan et al., 2005) and genetic activation of AMPK (Mair et al.,
2011) in nematodes reveals striking overlap (A. Rodrigues-Grant
and W.B.M., unpublished data), suggesting that their effects on
healthy aging function via similar mechanisms.
Rapamycin, Aspirin, and Direct AMPK Agonists
The National Institute on Aging recently implemented an inter-
vention testing program (ITP) to evaluate the ability of candidate
small molecules to prolong lifespan of genetically heterogeneous
mice. The highlight of the ITP to date has been the lifespan-ex-
tending effects of late-onset supplementation of rapamycin (Har-
rison et al., 2009). Rapamycin, a macrolide originally used as an
immunosuppressant for recipients of organ transplantation, acts
primarily through inhibition of TORC1. In worms, flies, and mam-
mals, rapamycin prolongs lifespan and protects against several
age-related diseases (Johnson et al., 2013; Lamming et al.,
2013). Suppression of mammalian TOR (mTOR) is one of the
key outputs of AMPK (discussed below), and rapamycin may
therefore phenocopy some effects of AMPK. The ITP is also
currently testing aspirin, which has been shown to increase
worm lifespan (Ayyadevara et al., 2013) dependent upon
AMPK (Wan et al., 2013). Interestingly, aspirin is rapidly metabo-
lized to salicylate, which was recently shown to directly agonize
AMPK (Hawley et al., 2012). Salicylate binds to AMPKb1, likely
interacting with the same site as the direct agonist A-769662
(Cool et al., 2006). It should therefore prove informative if specific
activators of AMPK, such as salicylate, A-769662, or the recently
reported C24 (Li et al., 2013), have similar beneficial effects on
lifespan as indirect agonists such as resveratrol and metformin.
AMPK and Aging Pathways
AMPK’s appeal as a target to promote healthy aging stems in
part from its ability to integrate multiple signaling and transcrip-
tional pathways known to promote longevity (Figure 2). However,
pervasiveness of feedback regulation within this network makes
Figure 2. AMPK Signaling and Aging Pathways
AMPK sits upstream of multiple signal transduction pathways known to modulate the aging process. Lines represent direct signaling effects. Color of line reflects
effect on target: green equals activating, red equals inhibiting. Color of modification equals effect of modification: green equals activating, red equals inhibiting.
Arrow signifies addition of a modification; T bar signifies removal of a modification. Therefore, for example, removing an inhibitory modification generates a green
T bar, as the effect on the target is activation. Orange factors are antilongevity, and blue are prolongevity.
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lenging and sometimes overly simplistic. This is especially the
case for aging research. Because invertebrates facilitate rapid
genetic analysis and have shorter lifespans, longevity mecha-
nisms are typically drawn from linear genetic epistasis of inverte-
brate models. Conversely, detailed signaling mechanisms are
often gleaned from mammalian tissue culture and extrapolated
back to invertebrates with little validation. Here, we review
both genetic and biochemical links between AMPK and key
longevity modulators across models.
TOR/S6K
As an intracellular nutrient sensor, TOR integrates amino acid
sensing with upstream signals from growth factor signaling path-
ways. The effect of TOR activation is a coordinated stimulation of
cellular processes that promote growth when nutrients are abun-
dant. AMPK and TOR therefore show opposing responses to
low cellular energy/nutrient status, being activated or repressed,
respectively. Interestingly, AMPK and TOR also show antago-
nistic effects toward many shared downstream processes,including autophagy, lipid metabolism, and protein synthesis
(Hardie et al., 2012; Laplante and Sabatini, 2012).
Given that AMPK and TOR are antagonistically regulated by
nutrients, one might expect that they have opposite effects on
aging, and indeed this is the case. In C. elegans, Drosophila,
and mice, downregulation of the TOR pathway prolongs lifespan
(Johnson et al., 2013). The prevailing view of the AMPK/TOR
interaction is that AMPK acts primarily as an upstream suppres-
sor of TOR. AMPK inhibits TOR signaling by two means: first,
AMPK phosphorylates the tuberous sclerosis protein 2 (TSC2),
which is an upstream inhibitor of TORC1 (Inoki et al., 2003); sec-
ond, it phosphorylates raptor to directly inhibit TORC1 (Gwinn
et al., 2008). However, recent work suggests that AMPK also
lies downstream of TORC1. The TORC1 target S6 kinase (S6K)
phosphorylates AMPKa2 at Ser491. AMPKa2 Ser491 phosphor-
ylation inhibits subsequent phosphorylation at Thr172 (Dagon
et al., 2012); thus, suppression of TORC1 can activate AMPK.
Possibly confirming this point, AMPKa/AAK-2 is required for
the longevity of C. elegans rsks-1/S6K mutants (Selman et al.,Cell Metabolism 20, July 1, 2014 ª2014 Elsevier Inc. 13
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TOR function together to mediate lifespan, the exact mecha-
nisms by which they exert their influences on longevity, and
which one is downstream of the other, remains unclear. At pre-
sent, themajority of work on the effects of AMPKon aging comes
from C. elegans, in which a TSC ortholog has yet to be identified
and where there remains no evidence that AMPK and TOR are in
fact coregulated.
FOXOs
Of the multiple nutrient- and energy-sensing pathways recently
identified to promote healthy aging, rIIS is the most potent,
robust, and least controversial (Kenyon, 2010). rIIS substantially
increases longevity and prolongs healthy aging inmultiple organ-
isms, including mammals (Kenyon, 2010). In C. elegans and
Drosophila, the sole FOXO transcription factor family member
is activated by rIIS and completely required for rIIS-mediated
longevity (Kenyon et al., 1993; Slack et al., 2011; Yamamoto
and Tatar, 2011). Highlighting the translational potential of this
pathway, SNPs in FOXO family members are linked to extreme
longevity in multiple human populations (Kenyon, 2010). In
C. elegans, aak-2 is required for the longevity effects of rIIS
(Apfeld et al., 2004). Suggesting that AMPK might activate
FOXO, induction of the stress-resistant dauer larval stage seen
in C. elegans with rIIS requires FOXO and is suppressed in ani-
mals lacking aak-2 (Apfeld et al., 2004). Furthermore, FOXO/
DAF-16 is required for lifespan extension via activating muta-
tions in the AMPK g subunit in C. elegans (Greer et al., 2007a).
AMPK can directly phosphorylate bothC. elegans (Greer et al.,
2007a) and mammalian (Greer et al., 2007b) FOXO family mem-
bers. However, it is not yet known if this event is causally or casu-
ally linked to lifespan extension. An alternative explanation for
the requirement of FOXO for AMPK longevity is that FOXO acts
upstream of AMPK or in a feedback loop. Indeed, DAF-16 has
been shown to regulate expression of multiple AMPK compo-
nents in C. elegans (Schuster et al., 2010; Tullet et al., 2014).
Reduced daf-16 may therefore deplete AMPK levels or alter
the composition of the heterotrimer. Although AMPK can directly
phosphorylate FOXO/DAF-16, it remains to be tested if this
interaction is required for AMPK longevity.
Sirtuins
AMPK is an appealing link between energetics and longevity
because it is directly activated by shifts in nucleotide balance
induced by low energy. However, ATP is not the only fuel whose
levels deplete under low energy. Reduced metabolic flux also
shifts balance toward a higher NAD:NADH ratio. One outcome
of this change is the activation of a class of deacetylases known
as the sirtuins, which require NAD for their enzymatic activity and
are heavily implicated in aging (Haigis and Sinclair, 2010). Initial
studies on the role of Sir2 and its orthologs in promoting aging
were hampered by confounding effects of genetic background,
enzymatic activity assays, and whether or not SirT1 is required
for all effects of DR (Lombard et al., 2011). However, subsequent
data demonstrate that activating Sir2 orthologs increases life-
span in specific yeast strains, worms, flies, and mice in the
absence of concerns over background effect (Guarente, 2013).
Despite their problems, excitement over the initial invertebrate
experiments spawned multiple experiments testing the effect
of sirtuins onmouse, and here the breadth of data shows without
doubt that these critical metabolic regulators have a role in age-14 Cell Metabolism 20, July 1, 2014 ª2014 Elsevier Inc.related pathology and might be targeted to promote healthy
aging (Guarente, 2013).
AMPK and sirtuins are therefore both critical fuel sensors with
positive effects on longevity, and there is substantial crosstalk
between them (Ruderman et al., 2010). Indeed, lifespan exten-
sion in C. elegans strains overexpressing the worm sirtuin,
sir-2.1, require aak-2 (Curtis et al., 2006), although these exper-
iments were done in lines harboring a mutation at an additional
locus, which may be confounding (Burnett et al., 2011). AMPK
can activate SirT1 by altering the NAD:NADH ratio (Canto´
et al., 2009; Fulco et al., 2008), and this interaction is critical for
maintaining energy homeostasis. Fasting induces a switch in
fuel usage from glucose to lipid in skeletal muscle mediated in
part by SirT1 promoting mitochondrial biogenesis and gene
expression via PGC-1 alpha in an AMPK-dependent manner
(Canto´ et al., 2010). AMPK also acts downstream of SirT1, as
mice lacking SirT1 show blunted activation of AMPK by either
resveratrol or AICAR administration (Price et al., 2012). SirT1
deacetylates and activates LKB1, leading to increased phos-
phorylation of AMPKa Thr172 (Lan et al., 2008). Therefore, as
is the case for mTOR, AMPK and SirT1 coregulate each other,
and how they coordinate to mediate lifespan requires further
evaluation.
CRTCs
Recently cAMP-responsive element-binding protein (CREB)-
regulated transcriptional coactivators (CRTCs) were shown to
link AMPK activity to the transcriptional regulation of lifespan
(Mair et al., 2011). CRTCs are transcriptional cofactors involved
in diverse physiological processes, including energy homeo-
stasis, mitochondrial biogenesis, and ER stress (Altarejos and
Montminy, 2011). CRTCs are direct targets of AMPK, and their
aberrant regulation is causal to multiple complex diseases (Altar-
ejos and Montminy, 2011). CRTCs were first identified as CREB
coactivators capable of inducing expression of CREB targets by
facilitating recruitment of the transcriptional apparatus (Conk-
right et al., 2003; Iourgenko et al., 2003), but CRTCs also interact
with bZIP transcription factors such as AP-1 and ATF-6 (Canet-
tieri et al., 2009; Wang et al., 2009b). CRTCs are negatively regu-
lated through phosphorylation by AMPK-family kinases, which
facilitates 14-3-3 protein binding and retention of CRTCs in the
cytoplasm (Screaton et al., 2004).
We investigated whether CRTCs played a role in mediating
the longevity effects of AMPK in C. elegans. There is a single
C. elegans CRTC family member, CRTC-1, that is expressed in
the nervous system and the intestine. Along with digestive func-
tion, the intestine is thought to play liver- and adipose-like roles in
the worm. CRTC-1 is inactivated by low nutrients and AMPK
(Mair et al., 2011). Mutating two conserved AMPK target serines
on CRTC-1 (S76 and S179) to alanine eliminates its regulation
by AMPK, resulting in constitutively nuclear and active CRTC-
1. Constitutively active (CA) CRTC-1S76A, S179A completely sup-
presses AMPK-mediated longevity.
Although the link between AMPK family kinases and CRTCs
is tightly conserved in Drosophila (Choi et al., 2011) and mam-
mals (Altarejos and Montminy, 2011), its effects on lifespan are
untested as of yet in these models. Mammals have three CRTCs
expressed predominantly in brain (CRTC1), liver (CRTC2), and
white adipose tissue (CRTC3). Each CRTC isoform can have
separable roles in distinct tissue types. For example, CRTC2
Figure 3. Physiological Effects of AMPK
Schematic of selected physiological effects on AMPK and the intermediate
mediators. Arrows signify activation, T bars signify suppression. Green sig-
nifies prolongevity, red signifies antilongevity.
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acts as an energy sensor in the hypothalamus (Lerner et al.,
2009), the area of the brain responsible for nutrient sensing.
Determining which tissue is responsible for the effect of CRTC-
1 on longevity will therefore provide valuable insight into the
mechanism of CRTC-1-mediated longevity, along with which
mammalian CRTC might be playing an analogous role.
Additional Longevity Mediators and AMPK
To date, TOR, rIIS/FOXO, sirtuins, and CRTCs are the pathways
most directly implicated in lifespan extension by AMPK. How-
ever, AMPK activity is associated with several additional known
longevity mediators, though causal association has yet to be
determined. For example, perturbed mitochondrial function ex-
tends lifespan in worms and flies, and in C. elegans this effect
is blunted in aak-2mutants (Curtis et al., 2006). A further link be-
tween mitochondrial perturbations, AMPK, and aging comes
from work on ‘‘I’m not dead yet’’ (INDY), which encodes a trans-
porter for Krebs cycle intermediates. Reduced indy expression
increases lifespan in C. elegans and Drosophila (Wang et al.,
2009a) and mimics the transcriptional effects of DR in mice (Bir-
kenfeld et al., 2011). Interestingly, INDY/ mice are protected
from HFD-induced obesity, have increased AMPK activity, and
increased hepatic mitochondrial density. Suggesting a causal
role for AMPK in the beneficial effects of INDY mice, the AMPK
inhibitor compound C has no effect on lipid synthesis in control
mice, yet increases fatty acid (FA) synthesis of INDY/ mice
by 240%. An additional link between AMPK and aging is the hyp-
oxia-inducible factor, HIF-1. Stabilization of HIF-1 in C. elegans
extends lifespan (Mehta et al., 2009), and in human prostate car-
cinoma cells, AMPK is required for HIF-1 activation by hypoxia
(Lee et al., 2003). However, lifespan extension under hypoxicconditions does not require AAK-2 in C. elegans (Leiser et al.,
2013), and as yet, a causal role of AMPK in HIF-1-mediated
longevity has not been tested. Importantly, the catalog of
AMPK substrates is unlikely to be complete. The kinase’s reach
has recently expanded into areas of biology where connec-
tions to aging or longevity remain underexplored, including, for
example, epigenetics (Bungard et al., 2010; Mihaylova et al.,
2011), circadian rhythm (Lamia et al., 2009), and mitosis (Banko
et al., 2011).
AMPK and Aging Processes
Aging does not result from the failure of a single homeostatic
mechanism; therefore, an ideal target for promoting longevity
will have widespread outcomes that globally promote cellular
homeostasis and repair. Here, we examine the effect of AMPK
on a variety of processes known to impact aging (Figure 3). We
highlight the gap between biochemical insights gleaned from
mammalian systems and the genetic and lifespan studies per-
formed in invertebrates.
Autophagy
Autophagy has emerged as a core process for longevity assur-
ance (reviewed in depth by Rubinsztein et al., 2011). Macroau-
tophagy (henceforth autophagy) is a highly conserved process
whereby a membrane-bound vesicle, the autophagosome,
engulfs cytoplasmic contents and delivers the enclosed intracel-
lular macromolecules and/or organelles to lysosomes for degra-
dation. The end result is a recycling of cellular components
to produce a fresh pool of intermediate compounds to accom-
modate the biosynthetic and energetic demands of the cell.
Autophagy also promotes molecular and organellar quality con-
trol by degrading damaged or misfolded proteins, and even
damaged mitochondria, in a process termed mitophagy. Most
longevity-promoting interventions require an intact autophagic
machinery; furthermore, reduced autophagic activity is associ-
ated with aging, while evidence suggests that enhanced auto-
phagy promotes longevity and delays age-related phenotypes
(Rubinsztein et al., 2011).
Since autophagy canmobilize preexisting cellular resources, it
becomes especially important when nutrients are scarce. As
such, DR is a potent inducer of autophagy, and AMPK plays
an important role in this process (Rubinsztein et al., 2011).
AMPK phosphorylates and activates UNC-51-like kinase 1
(ULK1), a conserved component of the autophagy initiation com-
plex (Egan et al., 2011; Kim et al., 2011a). ULK1 is required for the
formation of the autophagosome, and mammalian cells lacking
ULK1 display deficient basal mitophagy and sensitivity to starva-
tion (Egan et al., 2011). AMPK also regulates Vps34, a conserved
phosphatidylinositol 3-kinase (PI3K) that plays diverse roles in
the cell depending on the protein complex in which it resides.
In response to autophagy-inducing conditions or pharmacolog-
ical activation, AMPK differentially phosphorylates functionally
distinct Vps34 complexes such that proautophagy Vps34/
Beclin1/Atg14 complexes are activated by AMPK phosphoryla-
tion of Beclin1, while complexes without a role in autophagy
are inhibited by AMPK phosphorylation of Vps34 itself (Kim
et al., 2013).
AMPK may also regulate autophagy through interactions with
other longevity pathways. For example, rIIS is known to enhance
autophagy at least in some tissue types in worms, flies, andCell Metabolism 20, July 1, 2014 ª2014 Elsevier Inc. 15
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but whether FOXOs downstream of rIIS require a priming phos-
phorylation by AMPK to mediate autophagic responses is un-
known (Greer et al., 2007b; Mammucari et al., 2007). SirT1
directly deacetylates multiple components of the autophagic
machinery, and mice lacking SirT1 have deficits in basal auto-
phagy and AMPK activation and die shortly after birth (Lee
et al., 2008). Several recent studies highlight autophagy as a cen-
tral node for AMPK-TOR signal integration. mTOR phosphory-
lates ULK1 at a site closely neighboring AMPK phosphorylation
to inhibit the AMPK-ULK1 interaction and prevent activation of
autophagy (Kim et al., 2011a). Further, mTOR phosphorylates
and cytoplasmically sequesters the transcription factor EB
(TFEB), a master regulator of autophagic and lysosomal genes,
thereby inhibiting autophagy at the level of gene expression
(Settembre et al., 2011, 2012). The nematode ortholog of
TFEB, HLH-30, is required for multiple prolongevity interven-
tions, and upon overexpression, is sufficient for lifespan exten-
sion (Lapierre et al., 2013; O’Rourke and Ruvkun, 2013).Whether
AMPK directly regulates TFEB/HLH-30 is unknown, but it is
possible that AMPK enhances TFEB activity through its suppres-
sive effects on TOR. Lastly, transgenic activation of AMPK
and inhibition of calcineurin both extend longevity in C. elegans
by converging to regulate the activity of CRTC-1 (Mair et al.,
2011), and calcineurin longevity requires the autophagic
pathway (Dwivedi et al., 2009). While it has not yet been
determined whether longevity induced by AMPK requires the au-
tophagic machinery, it is tempting to speculate that CRTC ortho-
logs may play a role downstream of AMPK in the transcriptional
regulation of autophagy.
AMPK thus communicates with numerous pathways and pro-
teins to coordinate autophagy with cell and environmental con-
ditions, but more focused mechanistic studies are needed to
determine which mode of regulation, if any, plays a dominant
role in the context of aging. Invertebrate genetic analyses tell
us that numerous longevity pathways require intact autophagic
machinery, but dissecting which regulatory routes are important
for healthy aging remains difficult until the mostly mammalian-
defined signaling mechanisms delineated above have been
confirmed in worms or flies. As an example, Egan et al. (2011)
demonstrated that nematodes expressing a constitutively active
AMPKa display greater autophagosome numbers in an ULK1-
dependent manner, but both the biochemical interaction and
the requirement of this genetic interaction for AMPK-mediated
longevity remain unconfirmed. Demonstrating the promise of tar-
geting autophagy in mammals, overexpressing a key protein in
expansion of autophagosome membranes in mice enhances
autophagy, maintains metabolic fitness later in life, and extends
lifespan 17% (Pyo et al., 2013).
Mitochondrial Biogenesis
Mitochondrial homeostasis is linked to multiple pathways known
to modulate aging, and AMPK plays vital roles as both a sensor
and regulator of mitochondrial function. Mitochondrial activity
declines with age, while production of potentially toxic reactive
oxidative species (ROS) increases, in part through the impaired
ability of AMPK to generate newmitochondria in aged organisms
(Reznick et al., 2007). Although early hypotheses linking mito-
chondria to aging focused on ROS damage, we now appreciate
that mitochondria play diverse roles in processes as disparate as16 Cell Metabolism 20, July 1, 2014 ª2014 Elsevier Inc.apoptosis, intermediary metabolism, and calcium homeostasis,
and there is growing appreciation that ROS can play critical
signaling roles. Impairments of glucose metabolism and rIIS,
both of which require AMPK to increase lifespan (Apfeld et al.,
2004; Schulz et al., 2007), induce a transient increase in the
AMP/ATP ratio and trigger a burst of ROS production in nema-
todes (Zarse et al., 2012). This ROS signal promotes longevity
by signaling a lasting shift in mitochondrial function to increase
respiration and enhance antioxidant defense capacity, a process
termed mitohormesis, which requires aak-2/AMPKa (Schulz
et al., 2007).
Despite recent progress linking mitochondrial pathways to ag-
ing, how AMPKmediates crosstalk between mitochondrial func-
tioning and longevity-related pathways remains incompletely
understood, especially in worms and flies. In mammals, AMPK
is capable of both acute and long-term modulation of mitochon-
drial activity, controlling substrate selection for mitochondrial
fuel. In response to fasting and exercise, myocytes switch from
glucose to fat oxidation for energy, and AMPK is the driving force
for that switch (Canto´ et al., 2010). AMPK also remodels tran-
scriptional networks to control mitochondrial biogenesis and
turnover via mitophagy. Loss of two AMPKb units in murine mus-
cle reduces mitochondrial activity and greatly diminishes muscle
performance (O’Neill et al., 2011). Conversely, activation of
AMPK by AICAR (Winder et al., 2000) or energy deprivation
induced by guanidinopropionic acid (Zong et al., 2002) increases
mitochondrial gene expression and activity, and a 4-week treat-
ment of AICAR confers the benefits of endurance training to
sedentary mice in terms of both muscle mitochondrial profiles
and actual treadmill endurance (Narkar et al., 2008). The crit-
ical transcriptional effector of AMPK-mediated mitochondrial
biogenesis appears to be peroxisome proliferator-activated
receptor gamma coactivator-1a (PGC1a), a direct target of
AMPK phosphorylation (Ja¨ger et al., 2007). AMPK also promotes
SirT1 activity by increasing the cellular concentration of its
cofactor, NAD+, and SirT1 subsequently deacetylates PGC1a
(Canto´ et al., 2009). Interestingly, enhanced mitochondrial ho-
meostasis mediated by overexpression of Drosophila PGC1a
is sufficient to extend lifespan in flies, and while ubiquitous
PGC1a overexpression shortens lifespan, enhancing PGC1a
specifically in intestinal stem cells improves tissue maintenance
and promotes longevity (Rera et al., 2011). To date, however,
AMPK has not been linked to PGC1a in flies, and no PGC1a
ortholog has been identified in C. elegans. Taken together, we
know that AMPK senses and regulates mitochondrial homeo-
stasis in mammalian systems and that AMPK activity is sufficient
to promote lifespan in lower organisms. Importantly, however,
there is surprisingly little evidence that AMPK directly modulates
mitochondrial function in worms or flies, and thus it is too early to
conclude that AMPK promotes longevity through a mechanism
involving altered mitochondrial function.
Lipid Metabolism
Several lines of evidence link longevity downstream of rIIS, TOR,
and autophagy to global alterations in fat metabolism or lipid-
derived signaling pathways (Lapierre et al., 2011; O’Rourke and
Ruvkun, 2013; Soukas et al., 2009; Wang et al., 2008). Surpris-
ingly, despite AMPK’s involvement in these longevity pathways
and its long-established roles regulating lipid metabolism,
it remains unknown whether AMPK links lipid metabolism and
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presses metabolic homeostasis in mammals, paradoxically, in
lower organisms, longevity-promoting interventions such as rIIS
and DR can increase lipid deposition and accumulation (Hansen
et al., 2013). Current data suggest that differences in lipid compo-
sition (i.e., saturation, length) rather than amount might be more
critical in modulating the rate of aging. Supporting this concept,
long-lived germline-less worms activate a conserved pathway
involving a nuclear hormone receptor, NHR-80, and subsequent
enhancement of stearate desaturation to oleate via a stearoyl-
coenzyme A (CoA) desaturase (SCD) gene fat-6/SCD1 (Goudeau
et al., 2011). Similarly, overexpression of the lipase LIPL-4 in
C. elegans confers longevity by generating higher concentrations
ofu-6 fatty acids, which subsequently enhance autophagy (Lap-
ierre et al., 2012; O’Rourke et al., 2013;Wang et al., 2008). There-
fore, an important factor in agingmay not be altered adiposity per
se, but secondary intra- or intercellular lipokine signaling events
mediatedby lipid intermediates, and fatmobilization between tis-
sues. InDrosophila, DR enhances both triglyceride synthesis and
triglyceride catabolism, and this apparent cycling of fat involves
synthesis and mobilization of triglyceride between the fat body
and the muscle, where it is catabolized to support enhanced
tissue function (Katewa et al., 2012). Intriguingly, inhibition of fat
utilization in the muscle abrogates the lifespan effects of DR,
suggesting that the role of fat metabolism in aging involves
complex coordination of both lipid signaling and mobilization.
Consistentwith this idea, genetically arrested germline stemcells
in worms send signal(s) to the intestine to activate lipolysis, and
overexpression of the lipase responsible, LIPL-4, is sufficient to
promote longevity (Wang et al., 2008). While the growing number
of links between fat metabolism and aging are exciting, there
is still much to learn about the dynamics of fat utilization and
signaling.
As a core regulator of fat metabolism, AMPK is an important
piece in this puzzle, but investigations into whether AMPK medi-
ates its effects on aging through lipids are only now beginning.
AMPK inhibits the master regulator of lipogenesis, sterol regula-
tory element-binding protein (SREBP) via direct phosphorylation
(Li et al., 2011). In mammals AMPK also acutely alters the fate of
intracellular lipids, promoting beta-oxidation and suppressing
lipogenesis and sterol synthesis through targets such as
acetyl-CoA carboxylase 1 (ACC1) and ACC2, fatty acid
synthase (FAS), 3-hydroxy-3-methylglutaryl-CoA reductase
(HMGR), and glycerol-3-phosphate acyltransferase (GPAT) in
various tissues (Hardie et al., 2012), but many of these regulatory
links remain untested in invertebrate longevity models. A small-
molecule screen for compounds with effects on fat levels in
C. elegans identified a novel agonist selective for aak-1 (Lemieux
et al., 2011). The molecule also activated AMPK signaling in
mammalian cells, demonstrating both the utility of the worm for
screens involving organism-wide physiology and a conserved
role for AMPK in the global regulation of fat metabolism. Intrigu-
ingly, C. elegans AMPKa/AAK-2 mutants, which might be pre-
dicted to have suppressed lipid mobilization, burn through fat
stores faster than wild-type animals under conditions of starva-
tion, suggesting that AMPK rations fat reserves over the long
term and may be required for maintaining the levels of certain
lipid species (Narbonne and Roy, 2009). This general function,
if not the precise mechanism, seems conserved in flies (Bracoet al., 2012).Whether this role in fat rationing occurs to any extent
inmammals is unclear, but AMPKactivation in the adipose tissue
can inhibit hormone-sensitive lipase (HSL) and thus potentially
slow down lipolysis (Daval et al., 2005). Generally, many mecha-
nistic links between AMPK and lipid metabolism remain uncon-
firmed in worms and flies, and future studies probing AMPK
function in fat metabolism and aging will need to address both
its effect on lipid signaling and its role as a cell-autonomous
regulator of lipid utilization.
Central Control of Energy Homeostasis
Regulation of longevity by the central nervous system has
emerged from studies in worms, flies, and rodents (Alcedo
et al., 2013). Intriguingly, many of the neuronal subtypes associ-
ated with these longevity-related functions also sense or convey
changes in energy homeostasis across tissues. Consistent with
AMPK’s energy-sensing function at the cellular level, hormonal
orexigenic signals indicating low energy in peripheral tissues,
e.g., ghrelin, activate AMPK in the mammalian hypothalamus,
while anorexigenic signals indicating neutral or high energy sta-
tus, i.e., leptin, insulin, and high glucose, have the opposite effect
(Minokoshi et al., 2004). AMPK activation in this energy-sensing
region of the brain is sufficient to increase food intake and body
weight, thus restoring energy balance to the organism (Mino-
koshi et al., 2004). However, endogenous signals do not activate
AMPK universally across tissues. Leptin, for example, inhibits
AMPK in the hypothalamus while activating it in muscle (Mino-
koshi et al., 2002, 2004). In evaluating the potential for develop-
ment of a potent pharmacological activator of AMPK to increase
longevity, this particular role of the kinase presents an interesting
dilemma: will activating AMPK in the hypothalamus cause
hyperphagia, thus abrogating the beneficial metabolic effects
stemming from the periphery?
While a central role for AMPK in sensing and responding
to changes in energy homeostasis is conserved (Braco et al.,
2012; Cunningham et al., 2012), the extent to and mechanisms
by which central AMPK activity drives specific metabolic
processes in peripheral tissues remain mostly unexplored. In
response to activation by ghrelin, AMPK metabolically potenti-
ates the electrical hunger signal in NPY/AgRP neurons by
stimulating mitochondrial fatty acid oxidation through carni-
tine palmitoyl transferase 1 (CPT1)- and uncoupling protein 2
(UCP2)-dependent ROS scavenging (Stark et al., 2013). Intrigu-
ingly, ghrelin also stimulates CREB and FOXO transcription of
the NPY and AgRP neuropeptides, respectively, and activation
of these transcription factors requires CPT1 and UCP2, suggest-
ing that AMPK may be involved in this transcriptional pathway
as well (Lage et al., 2010). The precise molecular mechanism
connecting ghrelin and AMPK activity to CREB and FOXO re-
mains undefined, giving cause to speculate on a potential role
for CRTC orthologs in this pathway. Lerner et al. (2009) have
described an AMPK-CRTC interaction in the murine hypothala-
mus whereby AMPK inhibits CRTC2 to reduce expression of in-
sulin signaling components, e.g., Irs2. Future explorations in this
relatively young area of neuronal AMPK biology may determine
whether AMPK centrally and cell-nonautonomously promotes
longevity.
Stem Cells and Tissue Rejuvenation
Agedanimals display functional deficiencies across diverse tissue
types. In higher organisms, tissue function is compromised asCell Metabolism 20, July 1, 2014 ª2014 Elsevier Inc. 17
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to replenish somatic cells lost during normal wear and tear. This
suggests that prolonging the capacity of stem cells to rejuve-
nate tissues might confer longevity. Validating this concept,
longevity-promoting interventions including DR enhance stem
cell maintenance across broad evolutionary distances (Cerletti
et al., 2012; Mair et al., 2010). Though C. elegans lacks somatic
stem cells, worms arrest development in the absence of food
andcoordinatelyhaltproliferationof thegermline, aprocessdriven
by asymmetric division of germline stem cells (GSCs). Fukuyama
et al. (2012) and Narbonne and Roy (2006) have demonstrated
that AMPK is required for GSC quiescence in response to nutrient
deprivation in L1 larvae or dauer larvae, respectively. Further,
AMPK-deficient larvae that are fasted become sterile adults, sug-
gesting that AMPK is required for GSC function and/or viability
after nutrient stress (Fukuyama et al., 2012).
In mammals, LKB1 is required to maintain quiescence in he-
matopoietic stem cells (HSCs) (Gan et al., 2010; Gurumurthy
et al., 2010; Nakada et al., 2010). Mice with a conditional LKB1
knockout specifically in HSCs are short lived and initially display
increased proliferation followed by a pronounced depletion of
HSCs. LKB1 loss also results in altered HSCmitochondrial func-
tion and reduced ATP levels. Surprisingly, the data suggest that
neither AMPK nor mTOR is relevant to the observed effects on
HSC proliferation. Loss of AMPKa1/AMPKa2 phenocopies only
some mitochondrial deficits of the LKB1 null HSCs, but not
the depletion in cell numbers, and though mTOR activity is
enhanced, rapamycin also fails to rescue the effects on HSC
reconstitution (Nakada et al., 2010). More work is therefore
required to define the role of AMPK in mammalian stem cells
and tissue rejuvenation.
Protein Synthesis
Reductions in protein synthesis by knockdown of ribosomal
proteins or interference with translation initiation factors confer
longer lifespan across species (Kennedy and Kaeberlein,
2009). Reduced translation is also associated with longevity
mediated by both DR and TOR inhibition (Bjedov et al., 2010;
Hansen et al., 2007; Zid et al., 2009), and AMPK can reduce pro-
tein synthesis by one of several mechanisms. Activated by
anoxia or pharmacologically, AMPK acutely represses protein
synthesis by phosphorylating the upstream inhibitory kinase of
eukaryotic elongation factor 2 (eEF2) (Horman et al., 2002).
AMPK also regulates protein synthesis indirectly through its
crosstalk with the TOR pathway. Metformin treatment of cancer
cells leads to AMPK-dependent inhibition of mTOR and its
downstream targets, S6K and 4E-BP, to reduce protein syn-
thesis by 30% at the point of translation initiation (Dowling
et al., 2007). AMPK also suppresses global protein biosynthetic
capacity by reducing rRNA production (Hoppe et al., 2009).
Consistent with the tendency for long-term AMPK effects to
occur at the level of gene expression, this mechanism involves
AMPK-mediated phosphorylation and inhibition of TIF-IA, an
essential initiation factor for RNA polymerase I.
Despite these connections between reduced protein synthe-
sis, AMPK, and the DR or TOR longevity pathways, it is unclear
whether AMPK requires any of its effects on the translational
machinery to prolong lifespan. Further, though reduced protein
synthesis robustly extends lifespan across models, including
nematodes, which lack a clear 4E-BP ortholog, the mechanism18 Cell Metabolism 20, July 1, 2014 ª2014 Elsevier Inc.downstream of protein synthesis itself remains to be determined.
A recent study suggests that the beneficial effects may stem
from preferential synthesis of stress-protective proteins under
these conditions, as opposed to a decrease in total protein pro-
duction or concentration per se (Rogers et al., 2011). Future
application of techniques, such as polysome profiling or proteo-
mic analyses, to systems involving enhanced AMPK activity may
be informative in this regard.
AMPK and Aging Pathologies
Given its broad role in maintaining cellular and organismal
energy homeostasis, it is perhaps unsurprising that AMPK has
been implicated in multiple pathologies, including many age-
onset diseases reviewed extensively by Steinberg and Kemp
(2009). However, as outlined below, the concept of AMPK being
universally protective in age-related pathologies is oversim-
plistic. In the case of key age-onset diseases such as cancer
and neurodegenerative diseases, AMPK may even be patho-
genic. Here we discuss examples where AMPK can be both
protective and harmful for the same pathology, and as such,
how context is critical when thinking about targeting AMPK
therapeutically.
Cancer
Cancer cells undergo dramatic shifts in metabolism and override
checkpoints meant to coordinate growth with energy supply.
Perhaps unsurprisingly, AMPK deregulation has been implicated
in tumorigenesis. Type II diabetic patients taking metformin
show protection against cancer, independent of metformin’s
effects on diabetes (Gallagher and LeRoith, 2011). Metformin
also inhibits cellular transformation (Hirsch et al., 2013) and de-
lays p53/ tumor xenograft progression in mice (Buzzai et al.,
2007). Furthermore, mutations to LKB1 are commonly associ-
ated with sporadic non-small cell lung carcinoma and causally
linked to the inherited Peutz-Jeghers syndrome, which greatly
increases cancer risk. Additionally, multiple loss-of-function
LKB1 mouse models show a variety of cancer predispositions
(Shackelford and Shaw, 2009). Whether these effects specif-
ically result from AMPK inhibition, however, remains unclear.
LKB1 phosphorylates and activates a family of 14 AMPK-like
kinases, and redundancy between them may explain the infre-
quency of cancer-associated mutations in LKB1-dependent
kinases, including AMPK. Indeed, whether AMPK acts as a
tumor suppressor or in fact might be oncogenic is still uncertain
(Liang and Mills, 2013).
Recent work suggests that AMPK is a negative regulator of the
Warburg effect, a classical metabolic shift in cancer cells from
oxidative phosphorylation toward increased aerobic glycolysis
and lactate production, driving biomass production and growth.
AMPKa1-deficient mice overexpressing the oncogene c-Myc in
B lymphocytes have increased lymphomagenesis, with tumors
having increased glucose consumption and lactate production
(Faubert et al., 2013). Paradoxically, however, AMPK can also
support themetabolic changes needed to support tumor growth.
Enduring energy stress and hypoxia, cancer cells are effectively
living on the edge, and AMPK affords a metabolic plasticity that
allows them to survive (Jeon et al., 2012; Liu et al., 2012).
As such, under certain conditions, AMPK is—if not strictly onco-
genic—at least onco-enabling. These data may explain why
expression of AMPK components is often increased in human
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data such as the tumor suppressive effects of the direct AMPK
agonist A-769662 (Huang et al., 2008), more work is needed to
differentiate between contexts where AMPK activation is thera-
peutic and those where it may be detrimental.
Inflammation and Metabolic Disease
Metabolic disease is an age-associated pathology by which de-
regulated glucose homeostasis leads to hyperglycemia, glucose
intolerance, and insulin resistance. Given its role in maintaining
energy balance, AMPK has long been touted as a potential ther-
apeutic avenue, and metformin is one of the most widely pre-
scribed treatments for type II diabetes. Although the extent
to which AMPK mediates the beneficial effects of metformin on
metabolic disease remains unclear (Foretz et al., 2010; Miller
et al., 2013), there are multiple mechanisms by which this energy
sensor can restore glucose homeostasis. As discussed above
and reviewed comprehensively elsewhere (Hardie et al., 2012),
the classical role of AMPK is promoting a shift from anabolic to
catabolic processes, and thus activating AMPK might combat
metabolic disease by suppressing synthesis of fatty acids,
cholesterol, and triglycerides, while promoting fat burning via up-
regulation of beta-oxidation and mitochondrial biogenesis.
Increased and inappropriate glucose production is also associ-
ated with type II diabetes, and AMPK can suppress gluconeo-
genic genes through inhibition of CRTC/CREB targets (Koo
et al., 2005). AMPK additionally stimulates glucose uptake into
skeletal muscle by promoting translocation of the glucose trans-
porter GLUT4 to the plasma membrane (Hardie et al., 2012).
Together, these data suggest that activation of AMPK might
be a promising target for metabolic disease and may underlie
the striking protection of nonhuman primates on a DR regime
against type II diabetes-like symptoms (Mattison et al., 2012).
In addition to impaired glucose homeostasis, recent work has
pointed to a critical role for inflammation in metabolic disease
(Hotamisligil, 2006). Interestingly, proinflammatory cells such
as M1 macrophages and activated T cells undergo similar meta-
bolic shifts seen in tumor cells, including increased glycolysis
and flux through the pentose phosphate pathway. Conversely,
anti-inflammatory cells such as regulatory T cells andM2macro-
phages have reduced glycolysis, instead generating ATP via the
tricarboxylic acid (TCA) cycle and increased fatty acid meta-
bolism. AMPK dysfunction has therefore been suggested to be
a causal link between obesity and inflammation as well as a po-
tential therapeutic target (O’Neill and Hardie, 2013). In support of
this idea, anti-inflammatory cytokines activate AMPKa1 in mac-
rophages while proinflammatory stimuli suppress it (Sag et al.,
2008). Expression of a constitutively active form of AMPK also
increases anti-inflammatory M2 phenotypes. In addition, mice
with AMPKa1 deletion in macrophages have suppressed polar-
ization of the anti-inflammatory M2 macrophages in skeletal
muscle in vivo (Mounier et al., 2013). Taken together with its
effects on the NF-kb signaling (Salminen et al., 2011), AMPK is
therefore implicated as a central link between obesity, inflamma-
tion, and metabolic disease and is a potential therapeutic target.
Neurodegeneration
Deregulation of AMPK has been implicated in neurotoxicity-
related diseases. AMPK is highly expressed in brain and protects
against hippocampal neuron death during glucose deprivation
(Culmsee et al., 2001). Additionally, resveratrol and AICARincrease AMPK phosphorylation and decrease b-amyloid (Ab)
secretion from primary neurons in a mouse model of Alzheimer’s
disease (Vingtdeux et al., 2010), and this effect is blunted by the
AMPK inhibitor compound C. Resveratrol can be detected in the
brain of APP mice fed the compound, and these mice have
reduced soluble and insoluble forms of Ab (Vingtdeux et al.,
2010). Genetic activation of AMPK also protects against
neuronal loss in Parkinson’s disease models in Drosophila (Ng
et al., 2012). Conversely, inactivation of AMPK is linked to
increased Alzheimer’s risk in obese patients with type II diabetes
(Kim et al., 2011b). In line with this model, palmitate, a free
fatty acid associated with inflammation and obesity, sup-
presses AMPK and induces ER stress, tau phosphorylation,
and apoptosis in human neuroblastoma cells, and this effect is
blunted by AICAR and A-769662 (Kim et al., 2011b).
Much like tumorigenesis, however, AMPK’s role as a friend or
foe in neurodegenerative processes remains uncertain. AMPK is
often hyperactivated rather than suppressed in neurodegenera-
tive diseases (Vingtdeux et al., 2011), and it remains unclear if
this is a beneficial stress response or pathogenic. In the case
of Alzheimer’s, AMPK activation occurs via Ab-induced in-
creases in cellular calcium levels, which in turn stimulate the
AMPK-kinase CaMKKb (Thornton et al., 2011). Suggestive of a
pathological role of AMPK in neurodegenerative disease,
AMPK is a tau kinase and as such may be the mechanistic link
between Ab and tau hyperphosphorylation (Thornton et al.,
2011). Metformin also increases Ab levels in an AMPK-depen-
dent manner (Chen et al., 2009). AMPKa1 expression and
nuclear localization is also increased in mouse models of Hun-
tington’s disease (HD) and brains of HD patients (Ju et al.,
2011). In HD model R6/2 mice, this AMPK activation promotes
neuronal loss and brain atrophy (Ju et al., 2011). It therefore
remains to be determined if targeting AMPK will be useful thera-
peutically in neurodegenerative disorders and, if so, whether the
goal should be activation or inhibition.
Future Directions—Translating Genetics of Aging to
Therapeutics
Rather than targeting individual proximal causes of senescence
and disease, research into the molecular genetics of longevity
aims to beneficially impact a multitude of age-onset disorders
with a single intervention. AMPK represents a promising thera-
peutic target for promoting healthy aging, as it sits upstream of
multiple genetic pathways and homeostatic processes known
to mediate longevity. However, AMPK’s interconnected nature
perhaps limits its potential, since AMPK induces both beneficial
effects on longevity and detrimental physiological effects,
such as growth inhibition and reduced reproductive capacity in
invertebrates. Although activating AMPK may have therapeutic
potential in diverse disease models, the effects remain very
context specific, and in the case of age-onset disorders such
as cancer and neurodegeneration, AMPK may support disease
progression.
At present, the bulk of the biochemical and signaling data on
AMPK has been generated using mammalian systems, with
longevity data coming from invertebrates, where mechanisms
of AMPK action are often assumed rather than demonstrated
(Table 1). Defining how AMPK promotes longevity in lower or-
ganisms, and whether these effects are conserved in mammals,Cell Metabolism 20, July 1, 2014 ª2014 Elsevier Inc. 19
Table 1. AMPK-Related Effects across Model Organisms
Species C. elegans Drosophila Mouse
Lifespan Extension Observed upon:
AMPK activation U U ?
DR U U U
Metformin U ✕ U
Resveratrol U & ✕ U & ✕ ✕
Aspirin U ✕ ?
Direct AMPK Targets
FOXO U (DAF-16) ? (FoxO) U
TSC2 ✕ (none identified) ? (Tsc2) U
Raptor ? (DAF-15) ? (Raptor) U
CRTC U (CRTC-1) ? (CRTC) U
ULK1 ? (UNC-51) ? (Atg1) U
ACC1/ACC2 ? (POD-2) U (ACC) U
SREBP ? (SBP-1) ? (HLH106) U
AMPK Physiological Effects Observed upon:
Mitochondrial biogenesis ? ? U
Fatty acid oxidation ? ? U
Glycolysis ? ? U
Autophagy U U U
Activation of AMPK Observed upon:
DR U ? U & ✕
Metformin/phenformin U U U
Resveratrol ? ? U
Salicylate/aspirin ? ? U
Increased AMP:ATP ? U U
Check mark (U) signifies data showing positive effect, cross (✕) signifies
data showing no effect, and question mark (?) signifies effect unknown.
Invertebrate ortholog names are in parentheses.
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The conserved effects of AMPK on aging therefore represent just
the beginning of a field, and exciting challenges lie ahead if we
are to translate these data to useable therapeutics to promote
healthy aging.
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